美能联合格华止干预非酒精性脂肪肝预后观察

Observation on effects of compound glycyrrhizin combined with glucophage intervention in treatment of nonalcoholic fatty liver disease and prognosis

目的探讨分析美能联合格华止干预对非酒精性脂肪肝预后的临床效果。方法选取我院2012年1月至2013年1月门诊体检中心及住院治疗的诊断为非酒精性脂肪肝的患者80例，随机分为治疗组和对照组各40例。两组患者均采用综合治疗，对照组给予美能，3次／d，2片／次；治疗组在对照组的基础上加用格华止500mg／次，3次／d，总疗程3个月。观察两组疗效。结果治疗组有效率为85％，对照组为60％，两组比较差异有显著性（P〈0．05）；两组治疗后血脂及肝功能各指标比较差异有统计学意义（P〈0．05）；治疗后两组脂肪肝CT值比较差异有统计学意义（P〈0．05）。结论美能联合格华止干预治疗非酒精性脂肪肝预后效果显著，值得推广应用。

Objective To explore and analyze the clinical curative effect of compound glycyrrhizin combined with glucophage intervention to nonalcoholic fatty liver disease prognosis. Methods In our hospital from May 2012 to March 2013 in outpatient medical centers and hospital treatment, 80 patients with nonalcoholic fatty liver were divided into the treatment group and the control group, 40 cases in each, depending on the treatment, the control group was given only compound glycyrrhizin, 3 times/d, 2 tablets/time. Treatment group was added glucophage on the basis of the control group, 500 mg/time, 3 times/d, with the total course of 3 months. Effects were observed. Results The treatment group was 85%, 60% in the control group, showing statistical significant difference, P〈0.05; after treatment, blood lipids and liver function indicators difference were also statistically significant P〈0.05. After treatment, the fatty liver CT value of two groups showed a statistical significant difference, P〈0.05. Conclusion The compound glycyrrhizin combined with glucophage intervention has significant efficacy in treatment of nonalcoholic fatty liver prognosis, and should be widely applied.